Malaria infection during pregnancy is a significant public health problem with substantial risks for the pregnant woman, her foetus and the new-born child. Annually, around 125 million pregnancies around the world are at risk from malaria.1 Pregnant women with malaria face an increased risk of life-threatening outcomes, including cerebral malaria or severe anaemia, as well as unfavourable pregnancy outcomes such as miscarriages, premature delivery and low-birth-weight babies.2
As a recognized leader in antimalarial drug discovery, development and delivery, MMV aims to provide informed therapeutic choices for malaria treatment and protection across all genders and age categories, including pregnant and lactating women. For more information download MMV's MiMBa strategy.
Dellicour S et al. “Quantifying the Number of Pregnancies at Risk of Malaria in 2007: A Demographic Study”. PLos Med; 7(1): e1000221 (2010).
Schantz-Dunn J & Nour NM. “Malaria and Pregnancy: a global health perspective”. Rev Obstet Gynecol; 2(3):186–192 (2009).